AZD5069 Neutrophil Function Study

Study identifier:D3550C00017

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomised, Double-blind, Placebo-Controlled, Two-way Cross-over, Single Centre Study in Healthy Subjects to Assess the Effect of Oral Dosing of AZD5069 on Neutrophil Number and Function in Peripheral Blood and the Ability to Recruit Neutrophils into the Circulation after Exercise and Subcutaneous

Medical condition

Chemokine receptor 2 (CXCR2) antagonist

Phase

Phase 1

Healthy volunteers

Yes

Study drug

100 mg (50 mg x 2) AZD5069, 100 mg Placebo

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years - 45 Years

Date

Study Start Date: 01 Dec 2011

Primary Completion Date: 01 Jul 2012

Study Completion Date: 01 Jul 2012

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Aug 2015 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

Location

LONDON, UK, United Kingdom

Arms	Assigned Interventions
Experimental: 1 AZD5069 100 mg capsules (50 mg BD) for 7 days	Drug: 100 mg (50 mg x 2) AZD5069 Twice daily for 7 days
Experimental: 2 Placebo twice daily for 7 days	Drug: 100 mg Placebo Twice daily for 7 days

"There is no result for the study"

Documents available

CSR Synopsis
Download
Revised CS Protocol Redacted
Download
Trial Results Summaries
Available here

Contacts

Contact Backup

Suresh Babu

+44 207 910 7700

Suresh.Babu@quintiles.com

Investigators

Principal Investigator

Tim Mant

Quintiles research Unit